Nikolay Novitski/LinkedIn
May 5, 2026, 16:28
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:
”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.
Emerging therapies include:
- Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
- Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
- Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
- Muva (oral) – approximately an 86 percent reduction in Lp(a)
Important note:
- Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”
Stay updated with Hemostasis Today.
-
Jun 5, 2026, 03:27Lovish Garg: Restoring Venous Flow Through Catheter-Directed Thrombus Removal
-
Jun 5, 2026, 03:20Javed Anees: Anemia in Pregnancy Is Common, but Never Trivial
-
Jun 5, 2026, 02:52Andrada Seicean: Endoscopic Ultrasound and Portal Pressure Assessment in Patients Undergoing TIPS
-
Jun 5, 2026, 02:29Sam Tomy K: Antinuclear Antibody Testing and Its Role in Autoimmune Disease Diagnosis
-
Jun 5, 2026, 01:54Abdul Mannan: What Is the Most Common “Freeloading” Medication Seen in Anticoagulated Patients?
-
Jun 4, 2026, 17:38Francesco Tannura: The Potential of the Khorana Risk Score for PE Stratification in Lung Cancer
-
Jun 4, 2026, 16:17Nada Fahd: Immune Thrombocytopenia (ITP) – Outpatient vs Inpatient Management
-
Jun 4, 2026, 16:16Saoud Hassan: Hemostasis and Blood Coagulation Pathway – Simplified
-
Jun 4, 2026, 16:15Farooq Khan: Vacuuming Blood Clots in Seconds